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It has been postulated that the resident "passenger" 
leukocytes of hematolymphoid origin that migrate 
from whole organ grafts and subsequently establish 
systemic chimerism are essential for graft acceptance 
and the induction of donor-specific nonreactivity. 
This phenomenon was augmented by infusing 3x lOll 
unmodified donor bone-marrow cells into 40 patients 
at the time of organ transplantation. Fifteen of the 
first 18 analyzable patients had sequential immuno-
logical evaluation over postoperative intervals of 5 to 
17 months. (which included 7 kidney (two with islets), 
7 liver (one with islets), and one heart recipient). The 
evolution of changes was compared with that in 16 
kidney and liver nonmarrow controls followed for 4 to 
5 months. The generic immune reactivity of peripheral 
blood mononuclear cells (PBMC) was determined by 
their proliferative responses to mitogens (PHA. ConAl. 
Alloreactivity was measured by the recipient mixed 
lymphocyte reaction (MLR) to donor and HLA-mis-
matched third-party panel cells. Based on all 3 tests, 
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the recipients were classified as donor-specific hypo-
reactive, intermediate, and responsive; patients who 
were globally suppressed made up a fourth category. 
Eight (53%) of the 15 marrow-treated recipients ex-
hibited progressive modulation of donor-specific reac-
tivity (3 hypo reactive and 5 intermediate) while 7 
remained antidonor-responsive. In the nonmarrow 
controls. 2 (12.5%) of the 16 patients showed donor-
specific hyporeactivity, 10 (62.5%) were reactive. and 4 
(25%) studied during a CMV infection had global sup-
pression of responsiveness to all stimuli. 
We have proposed that the donor bone marrow-derived 
cells that migrate from transplanted organs and persist in 
the tissues of long-surviving recipients are essential for graft 
acceptance and the evolution of donor-specific nonreactlvity 
( I, 2). This spontaneous chimerism has been augmented in 
·W whole organ recipients by the perioperative infUSIOn of 
:)x 10"!kg unaltered donor bone marrow cells (3), We report 
here the sequential immunological evaluation of 15 of the 
first 18 analyzable recipients. In addition. 16 nonmarrow 
control recIpients of livers and kidneys were studied. To 
determine the development of donor specific hyporeactlvity 
in both cohorts. in vitro tests WE.'re performed monthly with 
the recipient's peripheral blood mononuclear calls (PBMC).* 
and the results were correlated with the clinical findings. 
• AbbreVlatlons: IL-2, interleukin 2; PBMC, peripheral blood 
mononuclear cells; PCR. polymerase cham reaction. 
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MATERIALS ru~a l\lETHODS 
Case material. Bone marrow group: All 40 patients given bone 
marrow augmentation are well. The present study was of 15 of the 
first 18. all adults. whose cases have been reported elsewhere 131. 
including details of marrow preparation. The dose of 3x lOHlcellikg 
unaltered bone marrow was given a few hours after organ revascu-
larizatlOn (3), Three of the first 18 recipients could not be evaluated. 
either because they had good MHC matches and consequent donor-
specific nonreactivity to begin with (n=2) or because donor cells were 
not available (n=1). No recipient conditioning was carned out. and 
postoperative immunosuppression with FK506 and prednisone did 
not differ from that used routinely (3). The 15 evaluated patients 
were recipients of 7 kidneys (2 with pancreatic islets I. 7 livers lOne 
with islets I, and one heart. Using HLA alleles of chromosomes 6 or 
the Y chromosome (after male-to-female transplants) as markers, all 
had readily detectable chimerism with F ACS, cytospin, or poly-
merase chain reaction (PCR) almost invariably with multiple tech-
nologies. This was estimated to be at least 1000 times greater than 
the microchimerism that occurs spontaneously (3). 
Nonmarrow controls: These 16 adults (5 kidney and 11 liver 
recipients) were from a consecutive series of 19 patients for whom 
donor bone marrow could not be obtained. The 3 exclusions from the 
analYSIS were for the same reasons of preexisting nonreactivitv or 
unavailability of samples as in the marrow group. Immunosuppres-
sion and other details of treatment were not different than In the 
study group. Blood microchimerism was present in 56% of the pa-
tients with PCR, but never as in the bone marrow cohort to the level 
detectable with FACS. 
In vitro immune monitoring. Mitogen response assays: PBMC 
were isolated from the recipient's heparinized blood by Ficoll-
Hypaque density centrifugation and resuspended at 106 cells/ml in 
tissue culture medium (RPMl 1640) supplemented with 5% pooled 
normal human serum (.J!. They were then incubated (105 celis/weill 
for 72 hr at 37°C in the presence of medium alone (backgroundl. 
concanavalin A (Con A) (4 !Lg/mll. or phytohemagglutinin (PHA) ( 10 
!J.g/m\) in a final volume of 200 !LI. For the last 18 hr of incubation. 
each well was pulsed with 1 !LCi of jH-thymldine (ICN Radiocheml-
cals, Cosa Mesa. CAl. and the uptake of radio activit v was measured 
by liquid scintillation counting. The results are expr~ssed as mean = 
SD of counts per minute. 
:\tixed lymphocyte response d\ILR): To mOnitor the development 
of donor-specltic h_vporeactivity. :\lLR assav was used with fresh Iv 
isolated reCipient cells as responders and the donor splenocvtes and 
control third-party HLA-unrelated panel cells as stimulators (s!. To 
determine the experimental variability and to assess the stimulatorv 
capacltv of the donor and other pa~el cells. each assav included 
PBMC obtained from normal individuals as control resp~ndersK Re-
cipients' PBMC were also used as stimulators for self and for normal 
PBMC responders. The MLR proliferative assay was set up for 6 
davs With responders (105 cells/well' and Y-Irradiated 1:2000 rads, 
stimulators ( 105 cells/weill in tissue culture medium supplemented 
with 5% human serum in a final volume of 200 !J.l. Proliferation was 
assessed as described above for the mitogen assays. 
Recipients' donor-specific MLR responses at various times post-
transplantation were compared with the recipients' pretransplant 
! posttransplant:pretransplant donor MLRI as well as with the re-
sponses of control third-party (donor MLR:third-party MLR [Di"I'P]I 
cells. Donor-specific hyporeactivity (category I I was defined as at 
least a 70% decrease in posttransplant vs. pretransplant donor-
specific MLR responses. while maintaining reactivity to both control 
third-party stimulator cells mrrp ratio < 40%) and to mitogens 
(>50% of pretransplant responses)' Donor-specific intermediate re-
activity (category In was designated when there was a 40-70'} 
inhibition of antidonor reactivity with retention of third-party re-
sponsiveness whereas reactive (category lIli meant that there was 
minimal or no decline in donor-specific nonreactivity. Suppression 
(category IV) connoted a nonspecific dimimshed proliferative re-
sponse to mitogens as well as to alloantigens. Representative exam-
ples of each of these 4 categories as measured at 3 postoperative 
months are shown in Table l. 
Limiting dilution analysis (LDA) of donor-specific helper T lym-
phocytes (HTLl: The frequency of donor-specific HTL was deter-
mined according to a previously described method (7). Briefly, van-
ous dilutions of irradiated recipients' PBMC (250R) were added as 
responders to round-bottomed microtiter wells that contained 5x 10' 
irradiated donor cells (2000R) in RPMI supplemented with ,,),} 
pooled human serum. After 48 hr of incubation at 37°C, an interleu-
kin 2 OL-2)-dependent T cell line (103 cells; CTLL-20) was added to 
each well for an additional 24 hr. Proliferation was measured bv 
pulsing the cultures for 6 hr with :lH-thymidine. Cultures wer~ 
considered positive for IL-2 release if cpm exceeded the mean plus 3 
SD of 3H-thymidine incorporation in 20 background control wells 
(microtiter wells that lack the responder cell!. Minimal frequency of 
HTL was calculated using a computer prO,,"TTam. the use of which has 
been described previously (8), and the results were expressed as 
HTUmillion cells. 
Propagation of graft-infiltrating cells: Small fragments of kidney 
core biopsies were used to propagate alloreactlve T cells in cultur~ 
E9FKq~e biopsies were teased into 4-fi small fragments and placed in 
mdlvldual wells of a 96-well round-bottomed microtiter plate in the 
presence of tissue culture medium supplemented with 5% human 
serum and 20 U/ml IL-2. Wells were rehTUlarlv observed for cellular 
proliferation from the biopsy and fed every !ilUrth day With IL-2. 
RESULTS 
Variability or donor-specijic reactivity. Representative ex-
amples of recipients' pre- and posttransplant proliferative 
responses, classified according to their In vitro reactivitv nre 
illustrated in Table 1. Recipient 1 (EM ~ kidnev) exhibited 
category I "donor-specific hyporeactivity" by th-ree months 
posttransplant, at which time the MLR response to donor 
T,\BLE 1. In vitro analysis of immune reactivity 
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TABLE 2. Donor-specific reactivity in bone marrow-augmented and 
control transplant recipients 
Donor-specific MLR Bone marrow- ControlG patterns augmentedG 
Hyporeactive POD 3 UK, 2L) 2 (lK, lL) 
(mean::!: smb 145::!:52 1I2::!: 10 
Intermediate POD 5 (2K, 3L) 0 
(mean ::!: SD)b 154::!:70 
Reactive 7 (4K, 2L. 1Hl 10 (2K, SL) 
Suppressed 0 4 (2K, 2L) 
a Number of transplant recipients: !K) kidney, (L) liver. IHl heart. 
/, Postoperative day when change in donor MLR reactivity was 
observed. 
TABLE 3. Immunosuppression and donor-specific reactivity in 
kidney transplant recipients-patterns of donor-specific MLR 
responses 
A. Kidney with BM 
Hyporeactlve Intennediate Reactive 
Patients (n) 1 2 4 
FK dose !mg/day) 4 20::!:3 21:!:14 
FK level (ng/mil O.S 0.9:!:0.05 0.S:!:0.3 
Steroids (mg/day) 0 0,2.5 11:!:3 
Azathioprine (mglday) 0 75 (1)0 75 (1)" 
Incidence of rejection 0 0 75% 
HLA mismatches 3 2, 5 1,5,5,6 
B. Kidney without BM 
Hyporeacti ve Suppressed Reactive 
Patients (n) 1 2 2 
FK dose (mg/day) 14 IS:!: 16 14:!:S 
FK level (ng/ml) 0.2 0.7:!:0.3 1.2::0 
Steroids (mg/day) 7.5 7.5,25 7.5:!:3.5 
Azathioprine (mg/day) 125 100 (llb 0 
Incidence of rejection 100% 100% 100% 
HLA mIsmatches 6 4. 5 3. 3 
., The two kidney-islets recipients who received azathiopnne. 
I> Number of patients. 
cells was significantly lower than that pretransplant (rela-
tive response 13%), whereas the proliferative responses to 
third-party and mitogens were not suppressed. In contrast, 
recipient 2 (BM + kidney) was considered a category II 
"donor-specific intermediate" responder since the donor-
specific MLR. though lower. was still 45'70 of pre transplant 
and the ratio of donor to third-party MLR was greater than 
'+0%. The Category III example ("reactivity") is exemplified 
hy BM .,- kidney recipient 3, in whom PBMC responses 
against the donor or third-party cells remained essentially 
unchanged. Liver control recipient 4 qualified for category IV 
(suppressed) because proliferative responses to all stimuli 
were signIficantly inhibited (this was characteristic during 
CMV infection). 
Eight (53'70) of the 15 bone marrow-augmented patients 
exhibited progressive modulation of donor-specific reactivity, 
3 (1 kidnev and 2 livers) with hyporeactivity and 5 (2 kidneys 
and 3 liv~rsF with intermediate antidonor responses. The 
other 7, including the heart recipient, remained reactive u 
to the last date tested (4-6 months postsurgery) (Table 2) 
In the nonmarrow control group, 2 (l3o/c-l kidney and 
liver) of the patients showed donor-specific hyporeactivity, 
who were studied during or shortly after CMV infection weT 
suppressed globally, and 10 remained vigorously reactive t 
donor cells (Table 2). 
Immune reactivity versus immunosuppression and gra[ 
function. Kidney recipients: The 3 (43%) of the 7 marrow 
treated recipients showing donor-specific hypo- (or interme 
diate) reactivity had no evidence of rejection: 2 recipients ar, 
ofT steroids and the third receives 2.5 mg/day prednison( 
(Table 3). In contrast, 3 (75%) of the 4 recipients who main 
tained vigorous antidonor reactivity underwent acute rejec 
tion episodes and are currently receiving 7.5-12.5 mg/day 0: 
prednisone. The two pancreatic islet recipients (one exhibit 
ing intermediate and the other reactive responses against 
the donor) are additionally receiving 75 mg/day of azathio-
prine. Both have evidence of plasma C-peptide activity but 
levels (0.44 and 0.11 pmoVmll are not high enough to permit 
an insulin-free existence. 
All 5 of the nonmarrow control recipients experienced 
transient rejection episodes. The only one classified as donor-
specific hypo reactive is being maintained on FK506 (14 mg! 
day), prednisone (7.5 mg/day), and azathioprine (125 mg/day) 
(Table 3). The higher drug requirement and persistently 
reactive immune status of the patients in the control group 
may reflect in part their shorter period of follow-up (137 = 24 
days) as compared with the patients in the study group 
(282= 113 days). However, the same general patterns were 
already identifiable within 90-120 days. 
The mean creatinine at the 4-month milestone and at the 
most recent follow-up was superior in patients in the marrow 
treated group compared with the controls (1.6=0.5 vs. 2.4+ 1 
mgldll. Both groups had similar rates of rejection in the first 
4 months (50% vs. 62%) and infection (20% vs. 25%). The 
TABLE 4. Immunosuppression and donor-specific reactivity in liver 
transplant recipients-patterns of donor-specific ~fio reactivity 
A. Liver with BM 
Hyporeactive !ntennediate ReactIve 
Patients (n) 2 3 2 
FK dose !mglday) 2.0::0 6.6:!:l 20::4 
FK level (nglml) O.2:!:0.1 0.33=0.2 O.5:!:0.4 
Steroids (mgJday) 0 5 (lla 5 (1)" 
Incidence of rejection 100'7, 33% 50% 
B. Liver WIthout 8M 
lIvporeacllve Suppressed ReactIve 
Patients (n I 2 H 
FK dose (mgJday I 10 1O::S 11 ::!:4 
FK level (ng/mll 0.4 0.65::0.07 1).6=0.3 
SterOIds (mgJday) 0 0 10=4 
(4)" 
Azathlopnne 1 mgJ 0 50 (1)0 0 
dayl 
InCidence of rejection 0% 100% 63% 
., !'lumber of patients. 
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e up degree of HLA matching did not influence graft function or 
2l. the frequency of donor-specific hyporeactivity (Table 3l. 
:l.d 1 As reported elsewhere \3), the chimerism was many-fold 
.y,4 more dense. with an incidence of 100% in the bone marrow 
>'ere group (one patient who shared 1B and 2 DR loci and same sex 
e to with the donor could not be followed). compared with low-
level chimerism in 609c of patients in the control group. 
"aft Liver recipients: A similar pattern was noted in the mar-
)W- row-augmented liver recipients compared with controls. The 
ne- bone marrow cohort had a higher rate of hypo- or intermedi-
lre ate antidonor reactivity \ 71 % vs. 27%), lower doses of immu-
me nosuppression, and a similar incidence of rejection and infec-
in- tion (Table 4). Liver function was equivalent in both groups. 
ec- Interestingly, as in the kidney series, there were no examples 
of in the bone marrow-treated patients of the global suppres-
it- sion noted in 25% of the controls. 
1St Two BM-augmented liver transplant recipients developed 
0- transient skin rashes that were diagnosed as GVHD by his-
ut topathology. One was treated with an increased dose of ste-
it roids (from 7.5 to 15 mg/day), whereas the other resolved 
spontaneously. The initial C-peptide activity of 0.83 pmol/ml 
d in the liver recipient also given pancreatic islets diminished 
- to 0.02 pmol/ml after an episode of acute cellular rejection 
~/ precipitated by withdrawal of immunosuppression to treat 
.) I colonic posttransplant lymphoproliferative disease (PTLD). 
v I The continued presence of donor DNA in the PBMC of liver 
J ! recipients was documented by PCR in all 7 patients in the 
. 
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FIGl:RE 1. Immunosuppression protile. rejection episodes (host-
versus-graft reJection: HGV1. and donor-specJtic MLR response dur-
Ing the tirst 12 postoperative months in a bone marrow and kidney 
transplant recipient. 
study group, whereas donor chimerism was detected in only 
54% (6/11) of patients in the control group (3l. 
Instability of donor-specific nonreactiuity. Three bone 
marrow-augmented patients who developed unequivocal 
early evidence of donor specific hypo- (DffP ratio 0.04 and 
0.07) or intermediate mffP ratio 30) reactivity lost this qual-
ity farther on in their course and became donor-reactive. 
The modulation of donor-specific MLR was significant in all 
three recipients (2614 vs. 33,933 cpm, 2986 vs. 20,619, and 
15,087 vs. 45,755 cpm, respectively) while their third-party 
MLR responses remained similar (mean reactivity ::!: SD: 
53,749::!:4545 cpm, 71,362::!:9036 cpm, and 40,726::!:4 cpm, 
respectively). All three patients underwent easily controlled 
late rejection: a liver-islet recipient (day 90), kidney-islet 
(day 232), and kidney (day 261). 
The events were similar in all 3 cases, epitomized by the 
course of a 25-year-old female recipient of a 5-HLA-matched 
male kidney (Fig. 1) in whom the presence of the Y chromo-
some allowed tracking of chimerism. After a bout of steroid-
treated rejection on day 16, her recovery was uncomplicated. 
After 4 months, she had developed donor-specific hyporeac-
tivity. Immunosuppression was reduced on day 175, and 
prednisone was eventually stopped. On POD 263, the serum 
creatinine increased, and a biopsy-proven rejection was suc-
cessfully treated with a steroid bolus and a transient increase 
in the FK506 dosage (Fig. 1). The infiltrating cells propa-
gated from the graft biopsy exhibited a 25-fold higher donor-
specific alloreactivity than that of the background controls. 
Two days preceding these events, a blood sample obtained on 
POD 261 showed an -6-fold increase in donor-specific reac-
tivity. The donor-specific helper T cells <HTL) were found to 
have increased three-fold from 15/106 cells (1 in 65,000 POD 
164) to 451106 cells (1 in 20,000 POD 232) one month prior to 
a rejection episode. She still maintains antidonor reactivity 
at the last date tested (POD 292). However. after successful 
treatment of rejection, a lymphocyte culture could not be 
propagated from a follow-up kidney biopsy. Throughout the 
course, the Y chromosome persisted in the patient's blood 
samples. 
DISCUSSION 
The premise upon which this study was based is that donor 
leukocyte chimerism is the essential basis for organ graft 
acceptance and the evolution of the donor-specific nonreac-
tivity that follows a characteristic cycle of immunologic crisis 
and resolution (J, 2l. With the demonstration that this spon-
taneous chimerism can be reliably and safely increased 
many-fold by bone marrow augmentation (3), it is possible to 
envision for the first time a future population of recipients of 
MHC-incompatible organs who can aspire to a drug-free 
state. 
However, it is equally clear that the enigmatic process 
leading to donor-specific nonreactivity is very gradual. One of 
the principal questions asked in this study is if the in vitro 
immune reactivity profile of the bone marrow treated pa-
tients was different. during the first few months, from that 
resulting from organ transplantation alone. According to the 
chimerism concept, the same leukocyte-dependent mecha-
nisms of graft acceptance are involved with or without adju-
vant bone marrow. 
Consequently, it was no surprise that the changes ob-
~erved in our marrow cohort were merely magnified and 
I 
I 
t' 
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I: 
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more frequent versions of those also seen in the control 
population. with no significant differences among recipients 
of various organs. Similar findings were noted often by others 
in conventionally treated recipients of various organs (10-
21), most frequently the liver (22), By themselves, the signif-
icance of the more pronounced and more frequent early 
changes in the bone marrow-augmented recipients would be 
difficult to assess. However. the remarkable benignancy of 
recovery in these patients and the accrual of 40 consecutive 
cases (kidneys, livers, and hearts) with no mortality com-
pared with less-satisfactory results in contemporaneous con-
trols (3) has added to our impression that the marrow en-
riched recipients' have gained a profound advantage without 
paying a commensurate penalty. Of special note was the fact 
that none of the 15 marrow-augmented patients treated with 
conventional immunosuppression had residual global sup-
pression (category IV) by the time of last testing. 
The second principal question is whether immunologic 
monitoring can guide the management of these patients, and 
provide signals about when it has become safe to wean drugs 
or stop them. Previous reports have emphasized the poor 
prediction index of in vitro tests for identification of stable 
tolerance in animal models (23, 24) or human organ recipi-
ents (25). The limitations of such analyses were illustrated by 
the 3 patients in the present study whose hyporesponsive-
ness was reversed after premature reductions ofimmunosup-
pression, with the onset of rejection. Because of the variabil-
ity of the outbred human population. it is hard to escape the 
conclusion that an element of trial and error will always be 
involved no matter how exhaustive the immune monitoring. 
Nevertheless, a role for immune monitoring is evident in 
these trials, if only because of the early warning that it can 
provide and for its use to assess the response to therapeutic 
course correction. It goes without saying that these exami-
nations are optimally useful only when they are done seri-
ally. Expansion of the test panel to include other methods 
may prove to be of practical value-and. in addition, these 
may provide more complete insight about the changes that 
occur at the interface between the donor and recipient cell 
populations. both of which retam immunologic reactivity. 
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